Physician profile
Amanda Penny
NPI 1942318589
$3,218.58
in general payments reported to CMS, 2019-2025
21 companies · $407 in 2025
The $407 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $214 · 2021: $432 · 2022: $505 · 2023: $630 · 2024: $572 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $631.85 | 2019-2024 | Jornay Pm |
| Corium, LLC | $413.94 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $362.28 | 2019-2025 | Bexsero, Pediarix |
| Tris Pharma INC | $341.85 | 2019-2024 | Dyanavel Xr |
| Pfizer INC. | $311.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $231.97 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $198.84 | 2019-2022 | |
| Sanofi Pasteur INC. | $171.87 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $134.99 | 2021-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $87.67 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $62.92 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $53.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $49.01 | 2022-2024 | Flumist Quadrivalent |
| Genentech USA, INC. | $39.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.88 | 2024 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $25.72 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.57 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.50 | 2025 | Neffy |
| Biomarin Pharmaceutical INC. | $13.65 | 2022 | |
| Kaleo, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Penny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.